Trial · NCT04802161
Results by group1,140
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,140
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Complete Response (CR)/Complete Response With Incomplete Hematologic Recovery (CRi) | Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide) | 9 | Participants | ||
| Rate of Complete Response (CR)/Complete Response With Incomplete Hematologic Recovery (CRi) | Arm B (Daunorubicin and Cytarabine Liposome) | 13 | Participants | ||
| Incidence of Adverse Events | Safety Run In DL1 (14 Days Pomalidomide) | Alanine Aminotransferase Increased | 4 | participants | |
| Incidence of Adverse Events | Safety Run In DL-1 (10 Days Pomalidomide) | Alanine Aminotransferase Increased | 2 | participants | |
| Incidence of Adverse Events | Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide) | Alanine Aminotransferase Increased | 8 | participants | |
| Incidence of Adverse Events | Arm B (Daunorubicin and Cytarabine Liposome) | Alanine Aminotransferase Increased | 8 | participants | |
| Incidence of Adverse Events | Safety Run In DL1 (14 Days Pomalidomide) | Aspartate Aminotransferase Increased | 6 | participants | |
| Incidence of Adverse Events | Safety Run In DL-1 (10 Days Pomalidomide) | Aspartate Aminotransferase Increased | 2 | participants | |
| Incidence of Adverse Events | Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide) | Aspartate Aminotransferase Increased | 8 | participants | |
| Incidence of Adverse Events | Arm B (Daunorubicin and Cytarabine Liposome) | Aspartate Aminotransferase Increased | 8 | participants | |
| Incidence of Adverse Events | Safety Run In DL1 (14 Days Pomalidomide) | Abdominal Distension | 0 | participants | |
| Incidence of Adverse Events | Safety Run In DL-1 (10 Days Pomalidomide) | Abdominal Distension | 0 | participants | |
| Incidence of Adverse Events | Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide) | Abdominal Distension | 1 | participants | |
| Incidence of Adverse Events | Arm B (Daunorubicin and Cytarabine Liposome) | Abdominal Distension | 0 | participants | |
| Incidence of Adverse Events | Safety Run In DL1 (14 Days Pomalidomide) | Activated Partial Thromboplastin Time Prolonged | 0 | participants | |
| Incidence of Adverse Events | Safety Run In DL-1 (10 Days Pomalidomide) | Activated Partial Thromboplastin Time Prolonged | 0 | participants | |
| Incidence of Adverse Events | Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide) | Activated Partial Thromboplastin Time Prolonged | 2 | participants | |
| Incidence of Adverse Events | Arm B (Daunorubicin and Cytarabine Liposome) | Activated Partial Thromboplastin Time Prolonged | 0 | participants | |
| Incidence of Adverse Events | Safety Run In DL1 (14 Days Pomalidomide) | Acute Kidney Injury | 0 | participants | |
| Incidence of Adverse Events | Safety Run In DL-1 (10 Days Pomalidomide) | Acute Kidney Injury | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04802161/results